# FDA 483 - CDYMAX (INDIA) PHARMA PRIVATE LIMITED - February 28, 2025

Source: https://www.keypedia.com/records/483/cdymax-india-pharma-private-limited/86b3641b-018a-4026-8442-dd024e713f8b

> FDA 483 for CDYMAX (INDIA) PHARMA PRIVATE LIMITED on February 28, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: CDYMAX (INDIA) PHARMA PRIVATE LIMITED
- Inspection Date: 2025-02-28
- Product Type: drugs
- Office Name: Office of Inspections and Investigations
- Summary: Cdymax (India) Pharma Private Limited, a drug manufacturer in Bangalore, India, was cited for deficiencies in laboratory records during an FDA inspection. The observations primarily concern incomplete data from tests, examinations, and assays, specifically regarding microbial enumeration test method suitability and inadequate isolate identification for both raw material monitoring and environmental monitoring in production areas. These issues indicate a lack of assurance in compliance with established specifications and standards.

## Related Officers

- [Eileen A. Liu](https://www.keypedia.com/people/eileen-a-liu/fa051db4-1242-4181-9af9-5b3cd2de5689)

Company: https://www.keypedia.com/companies/cdymax-india-pharma-private-limited/f1f48359-fb6a-47b2-8d2f-4106b353db6d

Office: https://www.keypedia.com/offices/office-of-inspections-and-investigations/7dd0b904-a3df-46bc-a7b2-70ddb6f809c8